Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Embold Phase III elecoglipron trial in adults with obesity or overweight with or without type 2 diabetes mellitus
2025-524688-19-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing Elecoglipron with Placebo for elecoglipron (2 arms). Primary endpoint: Percent change from baseline to Week 72 in body weight. Planned start Aug 2026; status: authorised.
02
Drugs
elecoglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-524688-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524688-19-00.